The list of winners for the 2025 Crystal Ball Awards for Listed Companies organized by Weekly on Stocks was recently unveiled. China Medical System Holdings Limited (the “Group” or “CMS”) has been honored with two prestigious awards — the 2025 “Shareholder Return Crystal Ball Award“ and the “ESG Crystal Ball Award“ for Listed Companies — in recognition of its outstanding capital market performance and leading ESG practices.
Launched in 2007 by Weekly on Stocks, the “Crystal Ball Awards” have become one of the three most influential annual award programs in China’s capital market, renowned for its professionalism, authority, and impartiality. The awards enjoy broad recognition among regulators, listed companies, and institutional investors.
CMS has entered a new stage as “an innovation-driven, multinational pharmaceutical company with a fully integrated R&D, manufacturing, and commercialization value chain“. Currently, the Group’s innovation pipeline has expanded to approximately 40 products, among which 5 innovative drugs have been approved for marketing, and another 5 products are under review for marketing application in China, demonstrating strong growth potential in the future. Meanwhile, CMS continues to advance its “industrial internationalization” strategy, with Singapore as the hub for emerging markets such as Southeast Asia and the Middle East. The Group has also completed the secondary listing on the Singapore Exchange Securities Trading Limited, further enhancing its global reputation and brand influence.
Since its IPO on the Hong Kong Stock Exchange (the “HKEX”) on September 28, 2010, CMS has steadfastly upheld prudent operations and long-term value creation, consistently delivering sustainable and substantial returns to shareholders and sharing the fruits of growth with investors worldwide:
- Maintained a high dividend payout ratio of 40% for 15 consecutive years;
- As of mid-2025, the accumulated cash dividends was71 billion, with RMB0.42 billion spent on accumulated share repurchases(cancelled), resulting in total shareholder returns of RMB10.13 billion, which is 12.2 times the net IPO proceeds (approximately RMB0.83 billion);
- If one purchased one share at the IPO issue price of HKD5.06 and held it for 15 years (including dividends and bonus shares), the annualized investment return rate would achieve 16.4%, with a 6.0x multipleof capital;
- In April 2025, the Group announced that its skin health business, Dermavon, proposed to be listed independently on the Main Board of The Stock Exchange of Hong Kong Limited (the “SEHK”)by way of introduction and with shares distributed in specie, allowing shareholders to share the independent value of this fast-growing business.
At the same time, CMS remains committed to green and low-carbon operations, continuous governance enhancement, and active participation in philanthropy and social welfare, promoting synergy between corporate value and societal well-being. Leveraging its sustained efforts and dedication in sustainable development, the Group has received multiple recognitions from domestic and international authoritative institutions:
- MSCI ESG rating maintains “AA”;
- S&P CSA Score is 66, outperforming 92% of global peers;
- HKQAA Sustainability Rating is in the top 10% of the industry;
- Wind ESG Rating is “AA”.
Looking ahead, CMS will continue to focus on its three core strategies “Product Innovation, Commercial Model Reform, and International Expansion“ while embedding ESG principles across all business operations, further expanding the breadth and depth of high-quality development. The Group strives to convert its business achievements into tangible value for shareholders, are committed to the position as a best practice among listed companies in the pharmaceutical industry, prioritizing steady growth with shareholder value creation.
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.